

10/ 573,352

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that

10/ 573,352

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:25:53 ON 23 FEB 2009

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 13:26:03 ON 23 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 FEB 2009 HIGHEST RN 1109311-46-7

DICTIONARY FILE UPDATES: 20 FEB 2009 HIGHEST RN 1109311-46-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10573352.str



chain nodes :
13 20 21 22 23
ring nodes :

10/ 573,352

3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19
chain bonds :
9-13 13-14 20-21 22-23
ring bonds :
3-4 3-8 4-5 4-9 5-6 5-12 6-7 7-8 9-10 10-11 11-12 14-15 14-19 15-16
16-17 17-18 18-19
exact/norm bonds :
9-13 13-14 20-21 22-23
normalized bonds :
3-4 3-8 4-5 4-9 5-6 5-12 6-7 7-8 9-10 10-11 11-12 14-15 14-19 15-16
16-17 17-18 18-19
isolated ring systems :
containing 3 : 14 :

G1: Ak, H

G2: H, CN, X


Hydrogen count :
11:= exact 1
Match level :
3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS 21:Atom
22:CLASS 23:CLASS 25:Atom 26:Atom
Generic attributes :
21:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :
Node 21: Limited
C, C4
N, N1

L1 STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1 STR

10/ 573,352



G1 Ak,H

G2 H,CN,X

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 13:26:33 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 42429 TO ITERATE

100.0% PROCESSED 42429 ITERATIONS

177 ANSWERS

SEARCH TIME: 00.00.01

L2 177 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

185.88

186.10

FILE 'CAPLUS' ENTERED AT 13:26:49 ON 23 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Feb 2009 VOL 150 ISS 9

FILE LAST UPDATED: 22 Feb 2009 (20090222/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

10/ 573,352

<http://www.cas.org/legal/infopolicy.html>


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 12

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L2 ANSWER 1 OF 177 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1092365-55-3 REGISTRY
ED Entered STN: 31 Dec 2008
CN 2-Buten-1-one, 4-bromo-1-[(3S)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-, (2E)- (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H20 Br Cl F2 N4 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.
Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 13:25:53 ON 23 FEB 2009)

FILE 'REGISTRY' ENTERED AT 13:26:03 ON 23 FEB 2009

L1 STRUCTURE UPLOADED

L2 177 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:26:49 ON 23 FEB 2009

FILE 'REGISTRY' ENTERED AT 13:26:55 ON 23 FEB 2009

FILE 'CAPLUS' ENTERED AT 13:26:56 ON 23 FEB 2009

=> s 12

L3 8 L2

10/ 573,352

=> d L3 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1483773 CAPLUS

DOCUMENT NUMBER: 150:35390

TITLE: Quinazoline-amide derivatives as cancer cell growth inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer

INVENTOR(S): Lee, Kwang-Ok; Cha, Mi Young; Kim, Mi Ra; Jung, Young Hee; Lee, Chang Gon; Kim, Se Young; Bang, Keukchan; Park, Bum Woo; Choi, Bo Im; Chae, Yun Jung; Ko, Mi Young; Kim, Han Kyong; Ahn, Young-Gil; Kim, Maeng Sup; Lee, Gwan Sun

PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea

SOURCE: PCT Int. Appl., 128pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2008150118	A2	20081211	WO 2008-KR3162	20080605
WO 2008150118	A3	20090129		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
KR 2008107294	A	20081210	KR 2008-52867	20080605
PRIORITY APPLN. INFO.:			KR 2007-54997	A 20070605

OTHER SOURCE(S): MARPAT 150:35390

GI



AB The invention provides quinazoline-amide derivs. of formula I and their pharmaceutically acceptable salts, (and a pharmaceutical composition comprising same as an active ingredient) which selectively and effectively inhibit the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor and also prevent the development of drug resistance caused by the mutation of EGFR tyrosine kinase. Compds. of formula I wherein A is (un)substituted propynoyl and (un)substituted acryloyl; R1 is (un)substituted (hetero)aryl; R2 is H, OH and (un)substituted C1-6 alkoxy; R2 is H, COOH, C1-6 alkoxy carbonyl and (un)substituted amido; D and E are independently (CH₂)₀₋₆; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multi-step procedure (procedure given). All the invention compds. were evaluated for their cancer cell growth inhibitory activity. From the assay, it was determined that II exhibited an IC₅₀ value of 4 nM against A431.

IT 1092364-02-7P 1092364-03-8P 1092364-04-9P
1092364-05-0P 1092364-06-1P 1092364-07-2P
1092364-08-3P 1092364-09-4P 1092364-10-7P
1092364-11-8P 1092364-14-1P 1092364-15-2P
1092364-22-1P 1092364-94-7P 1092364-95-8P
1092364-96-9P 1092364-97-0P 1092364-98-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of quinazoline-amide derivs. as cancer cell growth inhibitors useful in the treatment of cancer)

RN 1092364-02-7 CAPLUS

CN 2-Propen-1-one, 1-[(3S)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 1092364-03-8 CAPLUS

CN 2-Buten-1-one, 1-[(3S)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-, (2E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 1092364-04-9 CAPLUS

CN 2-Butyn-1-one, 1-[(3S)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1092364-05-0 CAPLUS

10/ 573,352

CN 2-Pentyn-1-one, 1-[(3S)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-5-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 1092364-06-1 CAPLUS

CN 2-Butyn-1-one, 1-[(3S)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1092364-07-2 CAPLUS

CN 2-Propen-1-one, 1-[(3S)-3-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 1092364-08-3 CAPLUS

CN 2-Propen-1-one, 1-[(3S)-3-[[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1092364-09-4 CAPLUS

CN 2-Propen-1-one, 1-[(3S)-3-[[4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1092364-10-7 CAPLUS

CN 2-Propen-1-one, 1-[(3S)-3-[[4-[(4-bromo-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)


10/ 573,352

Absolute stereochemistry.




RN 1092364-11-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1092364-14-1 CAPLUS
CN 2-Propen-1-one, 1-[(3S)-3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1092364-15-2 CAPLUS
CN 2-Propen-1-one, 1-[(3R)-3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)

10/ 573,352


Absolute stereochemistry.



RN 1092364-22-1 CAPLUS

CN 2-Propen-1-one, 1-[(3R)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1092364-94-7 CAPLUS

CN 2-Buten-1-one, 1-[(3S)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-4-(dimethylamino)-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.

10/ 573,352



RN 1092364-95-8 CAPLUS
CN 2-Buten-1-one, 1-[(3S)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-4-(diethylamino)-, (2E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 1092364-96-9 CAPLUS
CN 2-Buten-1-one, 1-[(3S)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-4-(4-morpholinyl)-, (2E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

10/ 573,352




RN 1092364-97-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1092364-98-1 CAPLUS
CN 2-Buten-1-one, 1-[(3S)-3-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-4-(dimethylamino)-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 1092365-53-1P 1092365-55-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

10/ 573,352


(Reactant or reagent)

(intermediate; preparation of quinazoline-amide derivs. as cancer cell growth inhibitors useful in the treatment of cancer)

RN 1092365-53-1 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-7-methoxy-6-[(3S)-3-pyrrolidinyloxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1092365-55-3 CAPLUS

CN 2-Buten-1-one, 4-bromo-1-[(3S)-3-[[4-[(3-chloro-2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:227766 CAPLUS

DOCUMENT NUMBER: 146:295946

TITLE: Preparation of quinazolines as EGFR tyrosine kinase inhibitors

INVENTOR(S): Himmelsbach, Frank; Jung, Birgit

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;
Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 48pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2007023073	A2	20070301	WO 2006-EP65000	20060803
WO 2007023073	A3	20070518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
CA 2619037	A1	20070301	CA 2006-2619037	20060803
EP 1919900	A2	20080514	EP 2006-778135	20060803
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009506990	T	20090219	JP 2008-527427	20060803
PRIORITY APPLN. INFO.:			EP 2005-107679	A 20050822
			WO 2006-EP65000	W 20060803
OTHER SOURCE(S):			CASREACT 146:295946; MARPAT 146:295946	
GI				



AB Title compds. [I; R1 = H, alkyl; R2 = H, F, Cl, Br, iodo, alkyl, OH, alkoxy, alkenyl, alkynyl, cyano, NO2, NH2, fluorinated Me, MeO; R3 = H, F, Cl, Br, Me, CF3; R4 = (substituted) cyclobutyl, cyclopentyl, cyclohexyl; R5 = H, F, Cl, Br, OH, alkoxy, fluorinated MeO, EtO, etc.; X = cyano-substituted methine, N], were prepared Thus, 4-[(3-chloro-4-fluorophenyl)amino]-6-[1-(hydroxymethylcarbonyl)piperidin-4-yloxy]-7-methoxyquinazoline was prepared by reaction of 4-[(3-chloro-4-fluorophenyl)amino]-6-(piperidin-4-yloxy)-7-methoxyquinazoline dihydrochloride with glycolic acid in the presence of N-ethylisopropylamine and TBTU in CH2Cl2 at room temperature Tested I inhibited EGF receptor kinase with IC50 <1000 nM preferably <100 nM.


IT 1070244-96-0 1070245-14-5

RL: PRPH (Prophetic)
(Preparation of quinazolines as EGFR tyrosine kinase inhibitors)

RN 1070244-96-0 CAPLUS


CN Ethanone, 1-[3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-

quinazolinyl]oxy]-1-pyrrolidinyl]-2-hydroxy- (CA INDEX NAME)



RN 1070245-14-5 CAPLUS

CN Ethanone, 1-[3-[[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-2-hydroxy- (CA INDEX NAME)



L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:300434 CAPLUS

DOCUMENT NUMBER: 142:374111

TITLE: Preparation of proline quinazoline derivatives as antiproliferative agents

INVENTOR(S): Bradbury, Robert Hugh; Halsall, Christopher Thomas; Hennequin, Laurent Francois Andre; Kettle, Jason Grant; Plowright, Alleyn

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Ltd.

SOURCE: PCT Int. Appl., 198 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030757	A1	20050407	WO 2004-GB4085	20040922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				


NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

AU 2004276055	A1	20050407	AU 2004-276055	20040922
CA 2540008	A1	20050407	CA 2004-2540008	20040922
EP 1670786	A1	20060621	EP 2004-768629	20040922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014735	A	20061121	BR 2004-14735	20040922
CN 1886399	A	20061227	CN 2004-80034739	20040922
JP 2007506716	T	20070322	JP 2006-527478	20040922
MX 2006003341	A	20060608	MX 2006-3341	20060324
US 20070043010	A1	20070222	US 2006-573352	20060324
NO 2006001743	A	20060621	NO 2006-1743	20060420


PRIORITY APPLN. INFO.:

GB 2003-22409	A	20030925
GB 2003-22534	A	20030926
WO 2004-GB4085	W	20040922

OTHER SOURCE(S): CASREACT 142:374111; MARPAT 142:374111
 GI



I



II

AB The invention relates to quinazoline derivs. I [R2 or the substituted pyrrolidinyloxy group is in the 6 or 7 position of the quinazoline ring; A is Ph or pyridyl; m is 0-3; n is 0-2; R1 is halo, cyano, nitro, hydroxy, carboxy, trifluoromethyl, alkyl, alkoxy, alkylsulfonyl, alkylureido, etc.; R2 is H, alkyl, cycloalkyl, cycloalkylalkyl or (un)substituted alkoxy; R3 is H, alkyl, cycloalkyl, alkylthio, alkylsulfinyl, carbamoylalkyl, etc.; R4 is alkyl, alkoxy, cyano, halo, hydroxy or oxo; R5 is H or alkyl; R6 is H, alkyl, alkoxy, heterocyclyl, heteroaryl, etc.; or R5R6N is a ring], including processes for their preparation, pharmaceutical compns. containing them,

and their use as antiproliferative agents in the prevention or treatment of tumors which are sensitive to inhibition of erbB receptor tyrosine kinases. Thus, compound II was prepared by etherification of Boc-protected cis-4-hydroxy-D-proline Me ester with 4-chloro-7-methoxyquinazolin-6-ol and reaction of the product with 3-chloro-2-fluoroaniline in 4.0 M HCl/dioxane and acetonitrile, followed by reductive N-methylation, saponification, and amidation. Compound II showed IC₅₀ = 0.008 nM for inhibition of EGFR tyrosine kinase protein phosphorylation and IC₅₀ = 0.144 nM in the EGFR driven KB cell proliferation assay.

IT 849345-01-3P 849345-02-4P 849345-03-5P
 849345-04-6P 849345-05-7P 849345-06-8P
 849345-07-9P 849345-08-0P 849345-20-6P
 849345-21-7P 849345-22-8P 849345-23-9P
 849345-24-0P 849345-25-1P 849345-26-2P
 849345-27-3P 849345-28-4P 849345-29-5P
 849345-30-8P 849345-31-9P 849345-32-0P
 849345-33-1P 849345-34-2P 849345-35-3P
 849345-36-4P 849345-46-6P 849345-47-7P
 849345-48-8P 849345-49-9P 849345-50-2P
 849345-51-3P 849345-52-4P 849345-53-5P
 849345-54-6P 849345-55-7P 849345-56-8P
 849345-57-9P 849345-58-0P 849345-59-1P
 849345-60-4P 849345-61-5P 849345-62-6P
 849345-63-7P 849345-64-8P 849345-65-9P
 849345-66-0P 849345-67-1P 849345-68-2P
 849345-69-3P 849345-70-6P 849345-71-7P
 849345-72-8P 849345-73-9P 849345-74-0P
 849345-75-1P 849345-76-2P 849345-77-3P
 849345-78-4P 849345-79-5P 849345-80-8P
 849345-81-9P 849345-82-0P 849345-83-1P
 849345-84-2P 849345-85-3P 849345-86-4P
 849345-87-5P 849345-93-3P 849345-94-4P
 849345-95-5P 849345-96-6P 849345-97-7P
 849345-98-8P 849345-99-9P 849346-00-5P
 849346-01-6P 849346-02-7P 849346-03-8P
 849346-04-9P 849346-05-0P 849346-06-1P
 849346-07-2P 849346-08-3P 849346-09-4P
 849346-10-7P 849346-11-8P 849346-12-9P
 849346-13-0P 849346-18-5P 849346-19-6P
 849346-20-9P 849346-21-0P 849346-22-1P
 849346-23-2P 849346-24-3P 849346-25-4P
 849346-26-5P 849346-27-6P 849346-28-7P
 849346-29-8P 849346-30-1P 849346-32-3P
 849346-33-4P 849419-45-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of proline quinazoline derivs. as antiproliferative agents)

RN 849345-01-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclopropyl-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849345-02-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(cyclopropylmethyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-03-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-methoxyethyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-04-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(cyclopentylmethyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)

10/ 573,352


Absolute stereochemistry.



RN 849345-05-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-methoxyethyl)-N,1-dimethyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-06-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-methoxy-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-07-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclohexyl-1-methyl-, (2R,4S)- (CA INDEX NAME)

10/ 573,352


Absolute stereochemistry.



RN 849345-08-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-(tetrahydro-2H-pyran-4-yl)-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-20-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(2-fluoro-4-methylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-21-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)


10/ 573,352

Absolute stereochemistry.



RN 849345-22-8 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-[[4-[(2-fluoro-4-hydroxyphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-23-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-[[4-[(2,4-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849345-24-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(2,5-difluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-25-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(4-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-26-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(4-chloro-2-fluorophenyl)amino]-7-methoxy-

10/ 573,352

6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-27-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(5-chloro-2-hydroxyphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-28-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-4-methoxyphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849345-29-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[[2-(aminosulfonyl)-5-chlorophenyl]amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-30-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[7-methoxy-4-[(2,3,4-trifluorophenyl)amino]-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

10/ 573,352




RN 849345-31-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-[[4-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849345-32-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-[[4-[[2-fluoro-3-(trifluoromethyl)phenyl]amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849345-33-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-methoxyphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-34-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-methylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-35-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-4-hydroxyphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849345-36-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-cyanophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-46-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849345-47-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-furanylmethyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-48-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-[(5-methyl-3-isoxazolyl)methyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-49-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[2-(1H-imidazol-1-yl)ethyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849345-50-2 CAPLUS

CN 2-Azetidinecarboxamide, 1-[[[(2R,4S)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-51-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(2R)-2,3-dihydroxypropyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-52-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-(1-methyl-1H-pyrazol-5-yl)-, (2R,4S)- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 849345-53-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-3-thienyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-54-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-(5-methyl-1H-pyrazol-3-yl)-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-55-7 CAPLUS

CN L-Serine, (4S)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-D-prolyl-, methyl ester (9CI) (CA INDEX NAME)

10/ 573,352


Absolute stereochemistry.



RN 849345-56-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-57-9 CAPLUS

CN Glycinamide, (4S)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-D-prolyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-58-0 CAPLUS

10/ 573,352

CN 2-Pyrrolidinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-59-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-[(3S,4R)-tetrahydro-4-hydroxy-3-furanyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-60-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[1-(hydroxymethyl)cyclopentyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849345-61-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-62-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[2-(1H-imidazol-5-yl)ethyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-63-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-methoxy-1-methylethyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849345-64-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-(2,2,2-trifluoroethyl)-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-65-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-2-propen-1-yl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-66-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-ethoxyethyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)

10/ 573,352


Absolute stereochemistry.



RN 849345-67-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-(2-methyl-2-propen-1-yl)-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-68-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(1S)-1-(hydroxymethyl)propyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-69-3 CAPLUS

10/ 573,352

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(2S)-2,3-dihydroxypropyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-70-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(1H-imidazol-2-ylmethyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-71-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[2-(2-furanyl)ethyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-72-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-73-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(1S)-2-hydroxy-1-methylethyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-74-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(1R)-2-hydroxy-1-methylethyl]-1-methyl-, (2R,4S)-

10/ 573,352

(CA INDEX NAME)


Absolute stereochemistry.



RN 849345-75-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(2R)-2-hydroxypropyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-76-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(2S)-2-hydroxypropyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849345-77-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-[[(2R)-tetrahydro-2-furanyl]methyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-78-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-[[(2S)-tetrahydro-2-furanyl]methyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-79-5 CAPLUS

CN Methanone, [(2R,4S)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl]-1-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849345-80-8 CAPLUS

CN Methanone, [(2R,4S)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-81-9 CAPLUS

CN Methanone, 1-azetidinyll[(2R,4S)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-82-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(cyanomethyl)-N,1-dimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849345-83-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(cyanomethyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-84-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,1-dimethyl-N-[(2S)-2-(1-pyrrolidinyl)propyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-85-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(1R)-2-hydroxy-1-methylethyl]-N,1-dimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849345-86-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,1-dimethyl-N-(1-methyl-4-piperidinyl)-, (2R,4S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 849345-87-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,1-dimethyl-N-(tetrahydro-2H-pyran-4-yl)-, (2R,4S)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 849345-93-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-

10/ 573,352

6-quinazolinyl]oxy]-1-methyl-N-2-propyn-1-yl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-94-4 CAPLUS

CN Methanone, [(2S,4R)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl] (2,5-dihydro-1H-pyrrol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-95-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(cyanomethyl)-1-methyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-96-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-

10/ 573,352

6-quinazolinyl]oxy]-N-(2-cyanoethyl)-1-methyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-97-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(cyanomethyl)-N,1-dimethyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-98-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-methoxyethyl)-N,1-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849345-99-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclopropyl-1-methyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-00-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclopentyl-1-methyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-01-6 CAPLUS

CN Methanone, [(2S,4R)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849346-02-7 CAPLUS

10/ 573,352

CN Methanone, [(2S,4R)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl][(3S)-3-hydroxy-1-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 849346-03-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(cyclopropylmethyl)-1-methyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-04-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclohexyl-N,1-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849346-05-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-

10/ 573,352

6-quinazolinyl]oxy]-1-methyl-N-(tetrahydro-2H-pyran-4-yl)-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-06-1 CAPLUS

CN Methanone, [(2S,4R)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl]-1-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-07-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N,1-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849346-08-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[2-(dimethylamino)ethyl]-1-methyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-09-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,1-dimethyl-N-(1-methyl-4-piperidiny)-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-10-7 CAPLUS

CN Ethanone, 1-[4-[[[(2S,4R)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849346-11-8 CAPLUS

CN Methanone, [(2S,4R)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl](4-hydroxy-1-piperidiny)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-12-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-methoxyethyl)-N,1-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849346-13-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclohexyl-1-methyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849346-18-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclopropyl-1-methyl-, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-19-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-methoxyethyl)-1-methyl-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849346-20-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclohexyl-N,1-dimethyl-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849346-21-0 CAPLUS

CN Methanone, [(2S,4S)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-22-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-(tetrahydro-2H-pyran-4-yl)-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849346-23-2 CAPLUS

CN Methanone, [(2S,4S)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl]-1-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849346-24-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(2-methoxyethyl)-N,1-dimethyl-, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-25-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,1-dimethyl-N-(1-methyl-4-piperidiny)-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849346-26-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclopentyl-1-methyl-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849346-27-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-methoxy-1-methyl-, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-28-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(cyclopropylmethyl)-1-methyl-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849346-29-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclohexyl-1-methyl-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849346-30-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-cyclopentyl-1-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-32-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849346-33-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(3-furanylmethyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 849419-45-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-(4-hydroxycyclohexyl)-1-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 849344-98-5P 849344-99-6P 849345-00-2P

849345-12-6P 849345-13-7P 849345-14-8P

849345-90-0P 849345-91-1P 849345-92-2P

849346-15-2P 849346-16-3P 849346-17-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of proline quinazoline derivs. as antiproliferative agents)

RN 849344-98-5 CAPLUS

CN D-Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849344-99-6 CAPLUS

CN D-Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-, methyl ester, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-00-2 CAPLUS

CN D-Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-12-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(4-cyano-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 849345-13-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-4-cyanophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-14-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[[3-chloro-4-(trifluoromethyl)phenyl]amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849345-90-0 CAPLUS

CN L-Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-, methyl ester, monohydrochloride, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 573,352




● HCl

RN 849345-91-1 CAPLUS

CN L-Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-, methyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849345-92-2 CAPLUS

CN L-Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 849346-15-2 CAPLUS

CN L-Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-, methyl ester, (4S)- (CA INDEX NAME)

10/ 573,352


Absolute stereochemistry.



RN 849346-16-3 CAPLUS

CN L-Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-, methyl ester, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849346-17-4 CAPLUS

CN L-Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:796670 CAPLUS

DOCUMENT NUMBER: 139:307787
 TITLE: Preparation of 4-anilinoquinazolines as
 antiproliferative agents
 INVENTOR(S): Bradbury, Robert Hugh; Hennequin, Laurent Francois
 Andre; Kettle, Jason Grant
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 190 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082831	A1	20031009	WO 2003-GB1306	20030326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479642	A1	20031009	CA 2003-2479642	20030326
AU 2003214443	A1	20031013	AU 2003-214443	20030326
EP 1487806	A1	20041222	EP 2003-710015	20030326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008670	A	20050201	BR 2003-8670	20030326
CN 1656081	A	20050817	CN 2003-811739	20030326
JP 2005529092	T	20050929	JP 2003-580299	20030326
JP 3891493	B2	20070314		
CN 101003515	A	20070725	CN 2007-10004468	20030326
NZ 535014	A	20070727	NZ 2003-535014	20030326
RU 2345989	C2	20090210	RU 2004-131683	20030326
US 20050215574	A1	20050929	US 2004-508675	20040922
MX 2004009486	A	20050125	MX 2004-9486	20040928
NO 2004004325	A	20041216	NO 2004-4325	20041012
JP 2006249093	A	20060921	JP 2006-102765	20060404
US 20080269487	A1	20081030	US 2008-147250	20080626
PRIORITY APPLN. INFO.:			GB 2002-7323	A 20020328
			GB 2002-30086	A 20021224
			GB 2003-1916	A 20030128
			CN 2003-811739	A3 20030326
			JP 2003-580299	A3 20030326
			WO 2003-GB1306	W 20030326
			US 2004-508675	A1 20040922
OTHER SOURCE(S):		MARPAT 139:307787		
GI				



AB The title compds. [I; G1, G2 = halo; X1 = a bond, O; R1 = H, alkyl, haloalkyl, etc.; X2 = a bond, (CR2R3)_m (m = 1-6; R2, R3 = H, OH, alkyl, hydroxyalkyl); Q1 = (un)substituted cycloalkyl, heterocyclyl] and their pharmaceutically acceptable salts, useful as an antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of erbB receptor tyrosine kinases, were prepared and formulated. Thus, reacting 4-(3-chloro-2-fluoroanilino)-6-hydroxy-7-methoxyquinazoline (preparation given) with 1-methyl-3-pyrrolidinol in the presence of PPh₃ and di-tert-Bu azodicarboxylate in DCM afforded 16% I.HCl [G1 = F; G2 = Cl; X1 = O; R1 = Me; X2 = a bond; Q1 = 1-methylpyrrolidin-3-yl]. The compds. I showed IC₅₀ in the range of 0.001-10 μM in EGFR tyrosine kinase phosphorylation assay.


IT 612500-77-3P 612501-00-5P 612501-01-6P
 612501-05-0P 612501-06-1P 612501-10-7P
 612501-11-8P 612501-14-1P 612501-18-5P
 612501-22-1P 612501-23-2P 612501-32-3P
 612501-44-7P 612501-84-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-anilinoquinazolines as antiproliferative agents)

RN 612500-77-3 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2-fluorophenyl)-7-methoxy-6-[(1-methyl-3-pyrrolidinyl)oxy]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 612501-00-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N-dimethyl-, (2S,4S)- (CA INDEX NAME)

10/ 573,352


Absolute stereochemistry.



RN 612501-01-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612501-05-0 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2-fluorophenyl)-7-methoxy-6-[[(3R)-1-(methylsulfonyl)-3-pyrrolidinyl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612501-06-1 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2-fluorophenyl)-7-methoxy-6-[[(3S)-1-(methylsulfonyl)-3-pyrrolidinyl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 612501-10-7 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2-fluorophenyl)-7-methoxy-6-[(3R)-1-methyl-3-pyrrolidinyl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612501-11-8 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2-fluorophenyl)-7-methoxy-6-[(3S)-1-methyl-3-pyrrolidinyl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612501-14-1 CAPLUS

CN Ethanone, 1-[(3R)-3-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 612501-18-5 CAPLUS

CN 1-Pyrrolidinesulfonamide, 3-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612501-22-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 612501-23-2 CAPLUS

CN Methanone, [(4R)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.


10/ 573,352



RN 612501-32-3 CAPLUS

CN Ethanone, 1-[(3R)-3-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-2-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 612501-44-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N,N,1-trimethyl-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612501-84-5 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2-fluorophenyl)-7-methoxy-6-[(1-methyl-3-pyrrolidinyl)oxy]- (CA INDEX NAME)

10/ 573,352



IT 612501-54-9P 612501-57-2P 612501-58-3P
612501-60-7P 612501-61-8P 612501-71-0P
612501-72-1P 612501-73-2P 612501-74-3P
612501-75-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of 4-anilinoquinazolines as antiproliferative agents)

RN 612501-54-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-
methoxy-6-quinazolinyl]oxy]-2-[(dimethylamino)carbonyl]-,
1,1-dimethylethyl ester, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 612501-57-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[(3-chloro-2-fluorophenyl)amino]-7-
methoxy-6-quinazolinyl]oxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX
NAME)

Absolute stereochemistry.


10/ 573,352



RN 612501-58-3 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2-fluorophenyl)-7-methoxy-6-[(3R)-3-pyrrolidininyloxy]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 612501-60-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 612501-61-8 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2-fluorophenyl)-7-methoxy-6-[(3S)-3-pyrrolidininyloxy]-, hydrochloride (1:1) (CA INDEX NAME)

10/ 573,352

Absolute stereochemistry.




● HCl

RN 612501-71-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612501-72-1 CAPLUS

CN Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 573,352

RN 612501-73-2 CAPLUS

CN Proline, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612501-74-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612501-75-4 CAPLUS

CN Methanone, [(2S,4R)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:


4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:796492 CAPLUS
 DOCUMENT NUMBER: 139:307786
 TITLE: Preparation of 4-(phenylamino)quinazolines as
 inhibitors of EGF-receptor kinase
 INVENTOR(S): Himmelsbach, Frank; Jung, Birgit; Solca, Flavio
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.,
 Germany
 SOURCE: PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082290	A1	20031009	WO 2003-EP3062	20030325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10214412	A1	20031009	DE 2002-10214412	20020330
DE 10231711	A1	20040122	DE 2002-10231711	20020713
CA 2476008	A1	20031009	CA 2003-2476008	20030325
AU 2003226705	A1	20031013	AU 2003-226705	20030325
AU 2003226705	B2	20081106		
BR 2003008902	A	20050104	BR 2003-8902	20030325
EP 1492536	A1	20050105	EP 2003-745271	20030325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005529090	T	20050929	JP 2003-579827	20030325
NZ 536114	A	20071130	NZ 2003-536114	20030325
IN 2004DN02255	A	20070112	IN 2004-DN2255	20040802
NO 2004003997	A	20041027	NO 2004-3997	20040923
MX 2004009536	A	20050125	MX 2004-9536	20040930
IN 2008DN07026	A	20080912	IN 2008-DN7026	20080818
PRIORITY APPLN. INFO.:			DE 2002-10214412	A 20020330
			DE 2002-10231711	A 20020713
			WO 2003-EP3062	W 20030325
			IN 2004-DN2255	A3 20040802
OTHER SOURCE(S):		MARPAT 139:307786		
GI				



AB Title compds. [I; R1 = H, C1-4 alkyl; R2 = (substituted) Ph, 1-phenylethyl; R3 = (amino-substituted) cyclobutyl, cyclopentyl, cyclohexyl; R4 = H, F, Cl, Br, alkoxy, (fluorinated) OMe, OCH₂CH₃, (substituted) alkyloxy, etc.; X = N, cyano-substituted CH], tautomers, stereoisomers, mixts., and salts thereof, especially the physiol. acceptable salts thereof with organic and inorg. acids, were prepared Thus, 4-[(3-chloro-4-fluorophenyl)amino]-6-hydroxy-7-methoxyquinazoline in MeCN was treated with (R)-3-hydroxytetrahydrofuran and Ph₃P followed by stirring with di-Et azodiformate over night at room temperature to give 15% 4-[(3-chloro-4-fluorophenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-methoxyquinazoline. The latter inhibited EGF-receptor kinase with IC₅₀ = 0.13 nM.

IT 1053774-97-2 1072544-68-3 1072544-69-4


1072544-70-7 1072544-71-8

RL: PRPH (Prophetic)

(Preparation of 4-(phenylamino)quinazolines as inhibitors of EGF-receptor kinase)


RN 1053774-97-2 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[[1-(methylsulfonyl)-3-pyrrolidinyl]oxy]- (CA INDEX NAME)



RN 1072544-68-3 CAPLUS


CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[(1-methyl-3-pyrrolidinyl)oxy]- (CA INDEX NAME)



RN 1072544-69-4 CAPLUS


10/ 573,352

CN Ethanone, 1-[3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 1072544-70-7 CAPLUS

CN Ethanone, 1-[3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-2-methoxy- (CA INDEX NAME)



RN 1072544-71-8 CAPLUS

CN Methanone, [3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)



IT 610302-20-0P


10/ 573,352

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (phenylamino)quinazolines as inhibitors of EGF-receptor kinase)

RN 610302-20-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 610302-26-6P 610303-04-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (phenylamino)quinazolines as inhibitors of EGF-receptor kinase)

RN 610302-26-6 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[(3S)-1-(methanesulfonyl)-3-pyrrolidinyl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 610303-04-3 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[(3S)-3-pyrrolidinyl]oxy]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:793441 CAPLUS

DOCUMENT NUMBER: 139:292268

TITLE: Preparation of bicyclic heterocycles especially quinazolines as inhibitors of EGF-receptor kinase

INVENTOR(S): Himmelsbach, Frank; Jung, Birgit; Solca, Flavio

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

SOURCE: Ger. Offen., 38 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10214412	A1	20031009	DE 2002-10214412	20020330
CA 2476008	A1	20031009	CA 2003-2476008	20030325
WO 2003082290	A1	20031009	WO 2003-EP3062	20030325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003226705	A1	20031013	AU 2003-226705	20030325
AU 2003226705	B2	20081106		
BR 2003008902	A	20050104	BR 2003-8902	20030325
EP 1492536	A1	20050105	EP 2003-745271	20030325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642552	A	20050720	CN 2003-807242	20030325
JP 2005529090	T	20050929	JP 2003-579827	20030325
NZ 536114	A	20071130	NZ 2003-536114	20030325

US 20040048880	A1	20040311	US 2003-400370	20030327
US 6924285	B2	20050802		
IN 2004DN02255	A	20070112	IN 2004-DN2255	20040802
NO 2004003997	A	20041027	NO 2004-3997	20040923
MX 2004009536	A	20050125	MX 2004-9536	20040930
US 20050182043	A1	20050818	US 2005-83247	20050317
US 7119084	B2	20061010		
US 20060270672	A1	20061130	US 2006-497727	20060802
US 20090036676	A1	20090205	US 2008-72510	20080226
IN 2008DN07026	A	20080912	IN 2008-DN7026	20080818
PRIORITY APPLN. INFO.:			DE 2002-10214412	A 20020330
			US 2002-381176P	P 20020516
			DE 2002-10231711	A 20020713
			WO 2003-EP3062	W 20030325
			US 2003-400370	A3 20030327
			IN 2004-DN2255	A3 20040802
			US 2005-83247	A1 20050317
			US 2006-497727	B1 20060802
OTHER SOURCE(S):		MARPAT 139:292268		
GI				




AB Title compds. [I; R1 = H, C1-4 alkyl; R2 = (substituted) Ph, 1-phenylethyl; R3 = (amino-substituted) cyclobutyl, cyclopentyl, cyclohexyl; R4 = H, F, Cl, Br, alkoxy, (fluorinated) OMe, OCH2CH3, (substituted) alkyloxy, etc.; X = N, cyano-substituted CH], tautomers, stereoisomers, and salts thereof, especially the physiol. acceptable salts thereof with inorg. or organic acids, were prepared Thus, 4-[(3-chloro-4-fluorophenyl)amino]-6-hydroxy-7-methoxyquinazoline in MeCN was treated with (R)-3-hydroxytetrahydrofuran and Ph3P followed by stirring with di-Et azodiformate over night at room temperature to give 15% 4-[(3-chloro-4-fluorophenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-methoxyquinazoline. The latter inhibited EGF-receptor kinase with IC50 = 0.13 nM.

IT 1053774-97-2
 RL: PRPH (Prophetic)
 (Preparation of bicyclic heterocycles especially quinazolines as inhibitors of EGF-receptor kinase)

RN 1053774-97-2 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[[1-(methylsulfonyl)-3-pyrrolidinyl]oxy]- (CA INDEX NAME)



L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:434373 CAPLUS

DOCUMENT NUMBER: 139:6886

TITLE: Preparation of quinazoline derivatives for the treatment of T cell mediated diseases

INVENTOR(S): Moore, Nelly Corine; Oldham, Keith

PATENT ASSIGNEE(S): Astrazeneca A.B., Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 217 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045395	A1	20030605	WO 2002-GB5222	20021120
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002343047	A1	20030610	AU 2002-343047	20021120
EP 1450808	A1	20040901	EP 2002-779708	20021120
EP 1450808	B1	20050615		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
AT 297733	T	20050715	AT 2002-779708	20021120
US 20050038050	A1	20050217	US 2004-496587	20040524
US 7160891	B2	20070109		
PRIORITY APPLN. INFO.:			GB 2001-28108	A 20011123
			WO 2002-GB5222	W 20021120
OTHER SOURCE(S):	MARPAT 139:6886			
GI				




AB Title compds. I [$m = 0-3$; $R_1 = \text{halo, CF}_3, \text{CN, NO}_2, \text{etc.}$; $R_2 = \text{H, alkyl}$; $R_3 = \text{H, alkyl}$; $Z = \text{bond, O, SO}_0-2, \text{amino, etc.}$; $Q_1 = \text{aryl(alkyl), cycloalkyl, cycloalkenyl, heteroaryl, etc.}$; $Q_2 = \text{phenyl}$] are prepared For instance, 4-[[2-chloro-5-ethoxyphenyl]amino]-5-hydroxy-7-methoxyquinazoline (preparation given) was coupled to 4-(3-hydroxypropyl)morpholine (CH_2Cl_2 , Ph_3P , $t\text{-BuO}_2\text{C-N=N-CO}_2\text{Bu-t}$) to give II. I are useful for the prevention or treatment of T cell mediated diseases.

IT 379231-23-9P, 7-Methoxy-5-[[N-methylpyrrolidin-3-yl]oxy]-4-[[2-bromo-5-methoxyphenyl]amino]quinazoline dihydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(quinazoline derivs. for treatment of T cell mediated diseases)

RN 379231-23-9 CAPLUS

CN 4-Quinazolinamine, N-(2-bromo-5-methoxyphenyl)-7-methoxy-5-[(1-methyl-3-pyrrolidinyl)oxy]-, hydrochloride (1:2) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:904160 CAPLUS

DOCUMENT NUMBER: 136:20087

TITLE: Preparation of 4-anilinoquinazoline derivatives for the treatment of tumors

INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 234 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094341	A1	20011213	WO 2001-GB2424	20010601
WO 2001094341	A9	20030417		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2407371	A1	20011213	CA 2001-2407371	20010601
EP 1292594	A1	20030319	EP 2001-934176	20010601
EP 1292594	B1	20040901		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001011335	A	20030610	BR 2001-11335	20010601
HU 2003001046	A2	20030828	HU 2003-1046	20010601
HU 2003001046	A3	20081229		
JP 2003535859	T	20031202	JP 2002-501890	20010601
JP 3774438	B2	20060517		
EE 200200673	A	20040615	EE 2002-673	20010601
NZ 522204	A	20040730	NZ 2001-522204	20010601
AT 275145	T	20040915	AT 2001-934176	20010601
PT 1292594	T	20041231	PT 2001-934176	20010601
ES 2225545	T3	20050316	ES 2001-934176	20010601
AU 2001260482	B2	20050609	AU 2001-260482	20010601
RU 2276151	C2	20060510	RU 2002-135617	20010601
CN 100345844	C	20071031	CN 2001-810830	20010601
TW 288748	B	20071021	TW 2001-90113714	20010606
IN 2002MN01457	A	20050304	IN 2002-MN1457	20021021
US 20040214841	A1	20041028	US 2002-275382	20021105
US 7049438	B2	20060523		
ZA 2002009122	A	20040209	ZA 2002-9122	20021108
MX 2002011765	A	20030410	MX 2002-11765	20021128
BG 107332	A	20030731	BG 2002-107332	20021128
NO 2002005792	A	20021202	NO 2002-5792	20021202
NO 324838	B1	20071217		
KR 807162	B1	20080227	KR 2002-716508	20021204

HK 1053115	A1	20050408	HK 2003-105395	20030725
KR 2008015055	A	20080215	KR 2008-702129	20080125
PRIORITY APPLN. INFO.:			EP 2000-401581	A 20000606
			EP 2001-400297	A 20010207
			EP 2001-400565	A 20010305
			WO 2001-GB2424	W 20010601
			KR 2002-716508	A3 20021204

OTHER SOURCE(S): MARPAT 136:20087
GI



AB The invention concerns quinazoline derivs. (I; e.g. 4-(2-chloro-5-methoxyanilino)-7-methoxy-5-(3-morpholinopropoxy)quinazoline (1)), processes for their preparation, pharmaceutical compns. containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease. Although biol. assay methods are described, no test results are reported. It is believed that the antitumor activity is due to inhibition of one or more of the non-receptor tyrosine-specific protein kinases of the Src family that are involved in the signal transduction steps that lead to the invasiveness and migratory ability of metastasizing tumor cells. In I, according to the 1st claim, m = 0-3; each R1 = halo, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulfamoyl, N,N-di[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, or Q3-X1- (X1 = direct bond, O, S, SO, SO2, N(R4), CO, CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, OC(R4)2, SC(R4)2 and N(R4)C(R4)2 (R4 = H or (1-6C)alkyl) and Q3 = aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-, (1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl), or (R1)m is (1-3C)alkylenedioxy, with addnl. optional substitution and/or insertion possible. R2 = H or (1-6C)alkyl; R3 = H or (1-6C)alkyl; Z = direct bond, O, S, SO, SO2, N(R11), CO, CH(OR11), CON(R11), N(R11)CO, SO2N(R11), N(R11)SO2, OC(R11)2, SC(R11)2 and N(R11)C(R11)2 (R11 = H, or (1-6C)alkyl). Q1 = aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,

(3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or, when Z is a direct bond or O, Q1 may be (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, halo-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio-(1-6C)alkyl, (1-6C)alkylsulfinyl-(1-6C)alkyl or (1-6C)alkylsulfonyl-(1-6C)alkyl, with addnl. optional substitution and/or insertion possible. Q2 = substituted Ph. More than 50 example preps. are included. For example, 1 was obtained by adding di-tert-Bu azodicarboxylate (0.208 g) dropwise to a stirred mixture of 4-(2-chloro-5-methoxyanilino)-5-hydroxy-7-methoxyquinazoline (0.2 g), 4-(3-hydroxypropyl)morpholine, PPh₃ (0.237 g) and CH₂Cl₂ (3 mL). The reaction mixture was stirred at ambient temperature


for 1

h.

IT 379231-23-9P, 4-(2-Bromo-5-methoxyanilino)-7-methoxy-5-((N-methylpyrrolidin-3-yl)oxy)quinazoline dihydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of anilinoquinazoline derivs. for treatment of tumors)

RN 379231-23-9 CAPLUS

CN 4-Quinazolinamine, N-(2-bromo-5-methoxyphenyl)-7-methoxy-5-[(1-methyl-3-pyrrolidinyl)oxy]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:25:53 ON 23 FEB 2009)

FILE 'REGISTRY' ENTERED AT 13:26:03 ON 23 FEB 2009

L1 STRUCTURE UPLOADED

L2 177 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:26:49 ON 23 FEB 2009

FILE 'REGISTRY' ENTERED AT 13:26:55 ON 23 FEB 2009

FILE 'CAPLUS' ENTERED AT 13:26:56 ON 23 FEB 2009

10/ 573,352

L3 8 S L2

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

XXXXXXXXXXXXXXXXXXXX

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-6.56	-6.56

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:28:33 ON 23 FEB 2009